Skip to main content

Table 2 Association between statin use after diagnosis and breast cancer-specific and all-cause mortality in patients with breast cancer

From: Statin use and breast cancer survival: a nationwide cohort study in Scotland

 

Breast cancer mortality

Patients

Person years

Age-adjusted HR (95 % CI)

P

Adjusteda HR (95 % CI)

P

[n = 15,140]

[n = 13,060]

Breast cancer mortality

 Statin non-user

855

10,907

30,852

1.00 (ref. cat.)

 

1.00 (ref. cat.)

 

 Statin user

335

4,233

10,421

0.87 (0.76,0.99)

0.04

0.95 (0.79,1.15)

0.62

 1-12 prescriptions

201

1,358

5,713

0.91 (ref. cat.)

0.22

0.94 (0.75,1.18)

0.61

 ≥12 prescriptions

134

2,875

4,708

0.82 (0.68,0.99)

0.04

0.97 (0.75,1.25)

0.79

 Simvastatin non-user

966

12,115

33,845

1.00 (ref. cat.)

 

1.00 (ref. cat.)

 

 Simvastatin user

224

3,025

7,428

0.82 (0.71,0.95)

0.01

0.89 (0.73,1.08)

0.24

 Lipophilic non-user

964

12,110

33,836

1.00 (ref. cat.)

 

1.00 (ref. cat.)

 

 Lipophilic user

226

3,030

7,437

0.83 (0.72,0.96)

0.01

0.90 (0.74,1.11)

0.33

 Hydrophilic non-user

1,062

13,434

37,389

1.00 (ref. cat.)

 

1.00 (ref. cat.)

 

 Hydrophilic user

128

1,706

3,884

0.95 (0.79,1.14)

0.57

0.97 (0.76,1.24)

0.82

All-cause mortality

 Statin non-user

1,323

10,907

30,852

1.00 (ref. cat.)

 

1.00 (ref. cat.)

 

 Statin user

684

4,233

10,421

0.95 (0.86,1.04)

0.27

0.88 (0.76,1.01)

0.07

 1–12 prescriptions

365

1,358

5,713

0.92 (0.82,1.04)

0.20

0.86 (0.73,1.02)

0.08

 ≥12 prescriptions

319

2,875

4,708

0.98 (0.86,1.11)

0.74

0.90 (0.75,1.08)

0.27

 Simvastatin non-user

1,527

12,115

33,845

1.00 (ref. cat.)

 

1.00 (ref. cat.)

 

 Simvastatin user

480

3,025

7,428

0.93 (0.84,1.04)

0.21

0.87 (0.75,1.00)

0.06

 Lipophilic non-user

1,525

12,110

33,836

1.00 (ref. cat.)

 

1.00 (ref. cat.)

 

 Lipophilic user

482

3,030

7,437

0.94 (0.85,1.04)

0.23

0.87 (0.75,1.01)

0.072

 Hydrophilic non-user

1,764

13,434

37,389

1.00 (ref. cat.)

 

1.00 (ref. cat.)

 

 Hydrophilic user

243

1706

3884

0.94 (0.83,1.08)

0.41

0.93 (0.77,1.11)

0.40

  1. aModel contains age, year of diagnosis, socioeconomic status, stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart disease, peripheral vascular disaese, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease), hormone replacement therapy use (in year prior to diagnosis), and other prescription medication use (tamoxifen, aromatase inhibitor and low-dose aspirin and metformin, as time varying covariates)